BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead.
The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG.
Get the full story at our sister site, Drug Delivery Business News.
The post BTG touts use of radiopaque drug-eluting bead appeared first on MassDevice.
from MassDevice http://bit.ly/2RQLn5X
Cap comentari:
Publica un comentari a l'entrada